This is especially true early in treatment, during dose increases, or on days when you feel full quickly
Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to reduce the risks of substance abuse disorders, psychosis, infections, some kinds of cancer and dementia, a sweeping new study suggests
The quite unexpected positive cardiorenal outcomes that have emerged from the cardiovascular outcomes trials (CVOTs) with both glucagon like peptide-1 receptors agonists (GLP-1RA) and sodium-glucose co-transporter 2 (SGLT-2) inhibitors have produced a shift of diabetes management from the meticulous glycemic control alone to the simultaneous improvement of CV outcomes
These can occur when hydration levels are not maintained consistently, especially with reduced food and fluid intake
In medical terms, microdosing generally refers to taking a dose lower than the lowest FDA-approved dose of a medication
Which lab markers does the fatigue article link to feeling drained on a GLP-1
